Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sagimet BiosciencesSTU:0O2 33 Capex-to-Operating-Cash-Flow is 0.00 as of Jun. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 33/100 and a GF Value™ of €5.69 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 240 Biotechnology companies, Sagimet Biosciences ranks worse than 416666.25% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Sagimet Biosciences Capex-to-Operating-Cash-Flow Related Terms
Sagimet Biosciences Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs CABA, OVID, QTTB: Capex-to-Operating-Cash-Flow Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Capex-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.00 mean?
Sagimet Biosciences (STU:0O2) has a Capex-to-Operating-Cash-Flow of 0.00 as of Jun. 2026. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #999999 out of 240 companies in the Biotechnology industry.
Is Sagimet Biosciences' Capex-to-Operating-Cash-Flow too high?
Sagimet Biosciences' current Capex-to-Operating-Cash-Flow is 0.00. Based on the distribution chart, Sagimet Biosciences ranks #999999 out of 240 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Capex-to-Operating-Cash-Flow compare to CABA and OVID?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #999999 out of 240 companies for Capex-to-Operating-Cash-Flow. This places Sagimet Biosciences in the lower half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Biotechnology company?
The median Capex-to-Operating-Cash-Flow among Biotechnology companies is 0.34, based on 240 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median Capex-to-Operating-Cash-Flow is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current Capex-to-Operating-Cash-Flow is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Sagimet Biosciences (STU:0O2) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.69, compared to a current price of €8.74 — trading 53.6% above its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.00. Sagimet Biosciences' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Capex-to-Operating-Cash-Flow is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sagimet Biosciences (STU:0O2) Overvalued in 2026?
Based on GuruFocus' analysis, Sagimet Biosciences stock appears to be overvalued.
The current stock price of €8.74 is trading 53.6% above its estimated GF Value™ of €5.69.
GuruFocus considers Sagimet Biosciences to be Significantly Overvalued.
Key valuation signals for STU:0O2:
Capex-to-Operating-Cash-Flow: 0.00
GF Value™: €5.69 vs. price of €8.74 (53.6% above fair value)
No single metric tells the full story. See the STU:0O2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
33GF Score
Get the complete analysis for STU:0O2
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
